<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082209</url>
  </required_header>
  <id_info>
    <org_study_id>M15-913</org_study_id>
    <secondary_id>2016-003887-37</secondary_id>
    <nct_id>NCT03082209</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies</brief_title>
  <official_title>An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose
      (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and
      pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid
      tumors or hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Anticipated">February 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration time curve (AUC) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Area under the serum concentration time curve (AUC) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Maximum observed serum concentration (Cmax) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination rate constant (β)</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination rate constant (β).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>The MTD and/or RP2D of ABBV-621 will be determined during the dose escalation phase of the study of ABBV-621</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Time to Cmax (Tmax) of ABBV-621.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcF Change from Baseline</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 42 days after first day of study drug administration or 14 days after bone marrow biopsy showing &lt; 5% blast count (whichever is later)</time_frame>
    <description>Dose limiting toxicities for dose escalation purposes will be determined on events that occur during the first 21-day cycle (with protocol specified exceptions for AML participants).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization for Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization for KRAS-mutant CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-621 Monotherapy for AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-621 + Venetoclax for AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-621</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Optimization for Pancreatic Cancer</arm_group_label>
    <arm_group_label>Dose Optimization for KRAS-mutant CRC</arm_group_label>
    <arm_group_label>ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <arm_group_label>ABBV-621 Monotherapy for AML</arm_group_label>
    <arm_group_label>ABBV-621 + Venetoclax for AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet, oral</description>
    <arm_group_label>ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <arm_group_label>ABBV-621 + Venetoclax for AML</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid
             leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose
             Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled
             to the cohort evaluating the combination of ABBV-621 and venetoclax. Subjects in the
             Dose Optimization solid tumor cohorts must have either colorectal cancer with
             documented KRAS mutations (as determined by local testing), or pancreatic cancer
             (irrespective of mutational status).

          -  Must have received at least one prior systemic therapy, and must have relapsed or
             progressed after, or failed to respond to any/all available effective therapy or
             therapies.

          -  Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST]
             1.1 for those with solid tumors; by Lugano classification for those with NHL), except
             those with AML, who must have histologically confirmed relapsed or refractory disease.

          -  Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2.

          -  Must have adequate hematologic, renal and hepatic function.

        Exclusion Criteria:

          -  Participants with history of brain metastases who have not shown clinical and
             radiographic stable disease for at least 28 days after definitive therapy.

          -  Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or
             hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater.

          -  Receipt of any systemic anti-cancer agent, including investigational anti-cancer
             products, within 21 days prior to study drug administration or 3 half-lives, whichever
             is longer.

          -  Participant with a history of cirrhosis or other indication of significant possible
             hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be
             discussed with the AbbVie TA MD before enrollment.

          -  Participant with a positive diagnosis of hepatitis A, B, or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ingalls</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Ctr Hosp East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Fundacion Jimenez Dia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Cancer</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>acute myeloid leukemia (AML)</keyword>
  <keyword>colorectal cancer (CRC)</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma (DLBCL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

